Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 18 Jul 2018 |
| Orion Corporation: Managers' transactions - Nina Karvonen | 20 Jun 2018 |
| Orion Corporation: Managers' transactions - Anne Karvonen | 20 Jun 2018 |
| Orion Corporation: Managers' transactions - EVK-Capital Oy | 31 May 2018 |
| Orion Corporation: Managers' transactions - Eija Ronkainen | 31 May 2018 |